Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
44.91
+0.79 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
A Preview Of Travere Therapeutics's Earnings
↗
October 30, 2024
Via
Benzinga
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
↗
October 23, 2024
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.
Via
Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
↗
October 21, 2024
Via
Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
↗
October 16, 2024
Via
Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
↗
October 10, 2024
Via
Benzinga
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 17, 2024
Via
Benzinga
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Where Travere Therapeutics Stands With Analysts
↗
September 27, 2024
Via
Benzinga
Analyst Ratings For Travere Therapeutics
↗
September 06, 2024
Via
Benzinga
Expert Ratings For Travere Therapeutics
↗
August 02, 2024
Via
Benzinga
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
October 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
↗
October 09, 2024
The company could soon ask for approval of its only drug, Filspari, in a second disease.
Via
Investor's Business Daily
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
↗
September 27, 2024
Via
Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
↗
September 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
September 26, 2024
Via
Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
Company to host conference call today at 4:30 p.m. ET
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
September 09, 2024
Via
Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
↗
September 06, 2024
Via
Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
↗
September 06, 2024
The company previously had an accelerated approval for its IgA nephropathy treatment.
Via
Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
↗
September 06, 2024
Via
Benzinga
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
